Paxlovid (Nirmatrelvir + Ritonavir)

Also known as: Paxlovid (Nirmatrelvir + Ritonavir)

Evidence Summary

Evidence Level: Moderate

Mechanism: Antiviral / Persistence, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Network

Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.

Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.

Investigational for listed conditions. 5 associated trial(s) and 3 study reference(s) in current data. Review primary sources and consult specialists before use.

Related Conditions

Long COVID (no page yet)

Clinical Trials

5 trial(s) registered

NCT07597902: SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction PHASE2 NOT_YET_RECRUITING

NCT05965726: RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms PHASE2 COMPLETED

NCT05595369: RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms PHASE2 COMPLETED

NCT05852873: PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway PHASE3 ACTIVE_NOT_RECRUITING

NCT05576662: Paxlovid for Treatment of Long Covid PHASE2 COMPLETED

Key Studies / References

PMID:42406565
PMID:42402140